210 likes | 228 Views
Schizophrenia: brain chemicals. How might neurotransmitters be implicated in mental illness?. Today’s session. Neurones. Neuronal cell bodies. Axons. Source: science photo library. Synapses occur at the junctions. Synapses. Neurones transmit signals electrically along their axons
E N D
Schizophrenia: brain chemicals • How might neurotransmitters be implicated in mental illness?
Neurones Neuronal cell bodies Axons Source: science photo library Synapses occur at the junctions
Synapses • Neurones transmit signals electrically along their axons • The synapses (junctions between neurones) transmit signals chemically
Synapse Vesicles filled with neurotransmitter Synaptic cleft Source: neuroscience.wustl.edu Location of receptors (post-synaptic density)
Excess neurotransmitter is taken up by the pre-synaptic neurone
The dopamine hypothesis • Schizophrenia is caused by excessive activity at synapses that use dopamine as their primary neurotransmitter • This causes abnormal functioning of DA-dependent brain systems, resulting in schizophrenic symptoms
Biology and Schizophrenia • Consistent evidence for abnormal brain functioning in S patients but no single factor identified. • Two syndromes? • Cause & effect issues everywhere • Confounding effects of drug treatment
Antipsychotic medication • Neuroleptics (e.g. chlorpromazine) bind to DA receptors without activating them
Effectiveness • Older (typical) drugs (e.g. chlorpromazine) • Short term beneficial effect in 75% of patients (Davis et al, 1989) • Long term beneficial effect in 55-60% (Davis et al, 1993) • Most effective against positive symptoms • High risk of side effects
Side effects • Extrapyramidal side effects (EPS) • Parkinson’s-type symptoms • Postural & motor abnormalities • Other side effects • Sedation • Weight gain • Seizures
What implications arise from the side effects of antipsychotic drugs?
Effectiveness • Newer (atypical) drugs (e.g. clozapine) • As effective as typical drugs on positive symptoms; better for negative symptoms (Bilder et al, 2002) • More effective with treatment-resistant patients (DeNayer et al, 2003) • Less risk of EPS, but other side effects may occur (e.g. blood disorders)
Typical vs. atypical tightly bound; slow release from receptor loosely bound; fast release from receptor Drug DA receptor